Bulking up immunity with instant Abs

Abstract

When Pfizer Inc. bought CovX Pharmaceuticals Inc. in 2007, the driver of the deal was the biotech's CovX-Body technology, which used a single antibody as a scaffold on which to build multiple product candidates that could be given via infusion. Pfizer may earn bonus miles from its acquisition, as CovX's cofounder at The Scripps Research Institute has now devised a way to produce the antibody therapeutics entirely in vivo, potentially obviating the need for infusions.